INMB - INmune says Alzheimer's study should finish on time despite FDA hold
2023-12-18 16:45:14 ET
More on INmune Bio
- INmune Bio, Inc. (INMB) Q3 2023 Earnings Call Transcript
- Capitalizing On Inflammation's Role In Neurological Disease Part 2: INmune Bio
- Seeking Alpha’s Quant Rating on INmune Bio
- Historical earnings data for INmune Bio
- Financial information for INmune Bio
For further details see:
INmune says Alzheimer's study should finish on time despite FDA hold